Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.37 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.37 |
| ▸ | TAOK3 | Q9H2K8 | 2/20 | 0.37 |
| ▸ | CTSK | P43235 | 3/20 | 0.36 |
| ▸ | CCR1 | P32246 | 2/20 | 0.35 |
| ▸ | CASP3 | P42574 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.35 |
| ▸ | MCOLN2 | Q8IZK6 | 1/20 | 0.34 |
| ▸ | MCOLN1 | Q9GZU1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6867039 | 0.87 | TAOK1 (0.43) | TAOK1TAOK3CTSKCCR1CASP3 | |
| SCHEMBL5848743 | 0.87 | TAOK1 (0.43) | TAOK1TAOK3CTSKCCR1CASP3 | |
| SCHEMBL5848731 | 0.87 | TAOK1 (0.43) | TAOK1TAOK3CTSKCCR1CASP3 | |
| SCHEMBL5848493 | 0.87 | TAOK1 (0.43) | TAOK1TAOK3CTSKCCR1CASP3 | |
| SCHEMBL5850513 | 0.87 | TAOK1 (0.43) | TAOK1TAOK3CTSKCCR1CASP3 | |
| SCHEMBL5848673 | 0.85 | CTSK (0.38) | TACR1TAOK1TAOK3CTSKCCR1 | |
| SCHEMBL5848379 | 0.84 | TAOK1 (0.37) | TACR1TAOK1TAOK3CTSKCCR1 | |
| SCHEMBL5848326 | 0.84 | TAOK1 (0.39) | TACR1TAOK1TAOK3CTSKCCR1 | |
| SCHEMBL5848411 | 0.84 | TAOK1 (0.37) | TACR1TAOK1TAOK3CTSKCCR1 | |
| SCHEMBL5848769 | 0.83 | TAOK1 (0.49) | TAOK1TAOK3CTSKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7008938-B2 | Benzene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient | NOKIA CORPORATION (FI) | 2006-03-07 | — | — | US | claimed |
| US-20050009755-A1 | Benzene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2005-01-13 | — | — | US | claimed |
| US-20030162964-A1 | Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient | NOKIA CORPORATION (FI) | 2003-08-28 | — | — | US | claimed |
| EP-1254898-A1 | BENZENE-FUSED HETEROCYCLE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-11-06 | — | — | EP | claimed |
| US-7008938-B2 | Benzene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient | NOKIA CORPORATION (FI) | 2006-03-07 | — | — | US | disclosed |
| US-20050009755-A1 | Benzene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2005-01-13 | — | — | US | disclosed |
| US-6809092-B2 | 1,3,4,5-TETRAHYDRO-2H-2-BENZAZEPIN-2-YL DERIVATIVES; CYSTEINE PROTEASE INHIBITORS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-10-26 | — | — | US | disclosed |
| US-20030162964-A1 | Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient | NOKIA CORPORATION (FI) | 2003-08-28 | — | — | US | disclosed |
| EP-1254898-A1 | BENZENE-FUSED HETEROCYCLE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162964-A1 | Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient | BACH1, BACE1, CMA1 | TACR1 3317/4885TAOK1 2279/4885TAOK3 3114/4885 |
| US-20050009755-A1 | Benzene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient | BACE1, BACE2, CBS | TACR1 3764/4885TAOK1 2998/4885TAOK3 3171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.